Zhang and colleagues investigated the efficacy of romidepsin in combination with erlotinib, which is an epidermal growth factor receptor (EGFR) tyrosine kinase receptor (TKI) in nine NSCLC cell lines with varying EGFR and KRAS mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.